Savara (SVRA) Total Non-Current Liabilities (2016 - 2025)

Savara (SVRA) reported Total Non-Current Liabilities of $50.3 million for Q4 2025, up 21.67% year-over-year from $41.3 million in Q4 2024, and up 8.09% on a QoQ basis from $46.5 million in Q3 2025.

Savara (SVRA) has 10 years of Total Non-Current Liabilities data on file, last reported at $50.3 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 21.67% year-over-year to $50.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.3 million (up 21.67% YoY) and the FY2025 annual result came in at $50.3 million, up 21.67% from the prior year.
  • Total Non-Current Liabilities rose to $50.3 million in Q4 2025 per SVRA's latest filing, from $46.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $50.3 million in Q4 2025 and bottomed at $29.6 million in Q1 2022.
  • The 5-year median for Total Non-Current Liabilities is $33.8 million (2021), against an average of $36.1 million.
  • The widest annual swing landed in 2021, when Total Non-Current Liabilities grew 21.73%; it then slipped 8.69% in 2022.
  • Tracing SVRA's Total Non-Current Liabilities over 5 years: stood at $32.0 million in 2021, then dropped by 0.12% to $31.9 million in 2022, then advanced by 15.65% to $36.9 million in 2023, then advanced by 11.9% to $41.3 million in 2024, then gained by 21.67% to $50.3 million in 2025.
  • Per Business Quant, the three latest SVRA Total Non-Current Liabilities figures stand at $50.3 million (Q4 2025), $46.5 million (Q3 2025), and $43.3 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Savara 1.30 Bn 1.30 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 50.30 Mn
Sep 30, 2025 46.54 Mn
Jun 30, 2025 43.28 Mn
Mar 31, 2025 41.42 Mn
Dec 31, 2024 41.34 Mn
Sep 30, 2024 39.34 Mn
Jun 30, 2024 37.77 Mn
Mar 31, 2024 36.23 Mn
Dec 31, 2023 36.95 Mn
Sep 30, 2023 35.24 Mn
Jun 30, 2023 32.10 Mn
Mar 31, 2023 31.07 Mn
Dec 31, 2022 31.95 Mn
Sep 30, 2022 31.17 Mn
Jun 30, 2022 29.65 Mn
Mar 31, 2022 29.63 Mn
Dec 31, 2021 31.98 Mn
Sep 30, 2021 32.01 Mn
Jun 30, 2021 31.02 Mn
Mar 31, 2021 32.45 Mn
Dec 31, 2020 33.28 Mn
Sep 30, 2020 29.62 Mn
Jun 30, 2020 28.35 Mn
Mar 31, 2020 26.66 Mn
Dec 31, 2019 33.99 Mn
Sep 30, 2019 33.25 Mn
Jun 30, 2019 33.87 Mn
Mar 31, 2019 34.11 Mn
Dec 31, 2018 31.85 Mn
Sep 30, 2018 25.19 Mn
Jun 30, 2018 23.29 Mn
Mar 31, 2018 23.36 Mn
Dec 31, 2017 28.37 Mn
Sep 30, 2017 44.13 Mn
Jun 30, 2017 34.32 Mn
Dec 31, 2016 11.24 Mn